Regulators Approve Controversial Obesity Drug

BMI View: Brazil's state regulator's decision to approve the sale and marketing of a widely banned weight loss supplement, even under strict conditions, raises concerns over patient safety. More importantly, BMI believes the disregard of international consensus signals that Brazilian health officials are willing to ignore drug efficacy even when alternative, safer treatments are

To read the full article, please choose one of the following options: